Ask Anything
LIVEESC Congress 2026Munich · Aug 28-31 · Hot Line trials and the live discussion from MunichOpen the hub→Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
ESC 2026 Hot LineRCT · n=5588 mentionsACC Journal Scan (X) Highlight
AUG 31KroupaNew England Journal of Medicine
Catheter-directed thrombolysis reduces mortality, PE recurrence, or decompensation ~90% vs standard anticoagulation.
Supports catheter-directed thrombolysis in intermediate-high-risk PE; confirms early-event reduction versus anticoagulation alone in this RCT.
VKViktor Kočka
In contrast to interventions for myocardial infarction or stroke, there have been very few advances in the treatment of [PE] over the last 20 years. This has led to a considerable unmet clinical need that we can't ignore.
ESC 2026 Hot LineRCT · n=9863 mentionsACC Journal Scan Highlight
AUG 30StähliNew England Journal of Medicine
TAVI followed by PCI is noninferior to PCI followed by TAVI for 1-year major events.
PCI timing in TAVR patients with CAD remains unresolved; leaves open whether omitting routine pre-TAVR PCI is safe.
ASACC Journal Scan
Importantly, this was not because coronary access was impaired after TAVI. Rather, once the valve had been treated, the clinical decision about whether PCI was still necessary sometimes changed.
ESC 2026 Hot LineRCT · n=9,97122 mentionsNEJM Highlight
AUG 28ZoungasNew England Journal of Medicine
Atorvastatin cuts major CV events ~30% vs placebo in older adults without improving disability-free survival.
Supports statin initiation for CV prevention in adults ≥70 without CVD; confirms event reduction in primary prevention but leaves disability-free survival benefit open.
ASACC Journal Scan
The risk of heart attack and stroke is a concern for older people and knowing there is an effective measure for lowering that risk will be a huge reassurance to older people and their families. We hope to see updated guidelines to help clinicians make use of these new findings.
ESC 2026 Hot LineRCT · n=51716 mentionsACC Journal Scan (X) Highlight
AUG 28MasriNew England Journal of Medicine
Aficamten improves KCCQ scores by 3 points and peak VO2 vs placebo at 36 weeks.
Provides first targeted option for symptomatic nonobstructive HCM; extends myosin inhibition beyond obstructive disease.
ASACC Journal Scan
For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
ESC 2026 Hot LineRCT · n=3607 mentionsExpert CommentaryACC Journal Scan Highlight
AUG 30HausleiterNew England Journal of Medicine
Transcatheter tricuspid repair cuts death or HF hospitalization ~60% versus medical therapy.
Supports transcatheter tricuspid repair plus medical therapy in symptomatic severe tricuspid regurgitation; delivers first randomized evidence of hard-endpoint benefit.
JHJörg Hausleiter
Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.
ESC 2026 Hot LineRCT · n=14,19417 mentionsMedscape Cardiology Highlight
AUG 29GibsonNew England Journal of Medicine
Milvexian shows no benefit over placebo for major cardiovascular events after recent ACS.
Milvexian adds no ischemic benefit after ACS; safety supports continued evaluation in ongoing atrial fibrillation and stroke prevention trials.
MCMedscape Cardiology
“Why is this important in terms of safety? Because milvexian is currently being evaluated in two other large trials: one in atrial fibrillation and one in secondary stroke prevention.”
ESC 2026 Hot Linecohort · n=16,80812 mentionsExpert CommentaryNEJM Highlight
AUG 29BundgaardNew England Journal of Medicine
Silent atherosclerosis affects ~57% of adults without known CVD, with plaque volume increasing with age.
Silent atherosclerosis is common from early adulthood without known disease; extends prevalence mapping but leaves open whether imaging changes primary prevention.
ASACC Journal Scan
Identifying and treating silent atherosclerosis as early as possible could help reduce the global burden of [cardiovascular disease]. Our findings support further prospective studies to investigate whether imaging-guided treatment of those with early evidence of disease – detected using a handhel...
ESC 2026 Hot LineRCT · n=35311 mentionsTrending on XExpert Commentary
AUG 28SelvanayagamJAMA
Primary prevention ICD fails to reduce sudden cardiac death or significant ventricular arrhythmias versus ILR.
Does not support primary prevention ICD in LVEF 36-50% with scar; challenges CMR late gadolinium enhancement alone for defibrillator selection.
JSProf. Joseph Selvanayagam
Cardiologist, Flinders University
In the CMR GUIDE trial, we assessed whether an ICD could improve outcomes in patients with LVEF 36-50% who have evidence of myocardial scarring, a risk factor for sudden cardiac death.
ESC 2026 Hot LineRCT · n=2,23410 mentionsNEJM Highlight
AUG 30ReedNew England Journal of Medicine
Immediate 14-day wearable ECG monitoring fails to reduce syncope episodes at one year versus standard practice.
Immediate 14-day ECG monitoring does not reduce syncope recurrence at 1 year; challenges routine adoption despite higher arrhythmia detection in unexplained syncope.
ASACC Journal Scan
Early ECG monitoring did not lead to lower recurrence of syncope than standard care. This finding probably reflects the multifactorial nature of syncope, with a clinically important arrhythmia identified in only 22.0% of the intervention group, a result that limited the effects of rhythm-directed...
ESC 2026 Hot LineRCT · n=2646 mentionsNEJM Highlight
AUG 30ZhangNew England Journal of Medicine
Pulmonary-artery denervation cuts 2-year clinical worsening ~51% versus medical therapy alone.
Pulmonary-artery denervation halves clinical worsening in PH-LHD; extends interventional options beyond medical therapy in this population.
ASACC Journal Scan
“Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure.”